Analysis

Lenz Therapeutics, Inc. (LENZ) Stock Analysis

Lenz Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to LENZ.

websiteLENZ/analysis/LENZ

Lenz Therapeutics, Inc.

Lenz Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to LENZ.

Stock profile

Ticker

LENZ

Asset type

Stock

Market cap

$192.8M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Lenz Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • LENZ primary listing

Latest Lenz Therapeutics, Inc. news

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc...

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Inve...

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ®...

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency ...

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, ...

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in

Research sections

Valuation

Review valuation context for Lenz Therapeutics, Inc..

Future growth

Review future growth context for Lenz Therapeutics, Inc..

Past performance

Review past performance context for Lenz Therapeutics, Inc..

Financial health

Review financial health context for Lenz Therapeutics, Inc..

Dividend

Review dividend context for Lenz Therapeutics, Inc..

Management

Review management context for Lenz Therapeutics, Inc..

Ownership

Review ownership context for Lenz Therapeutics, Inc..

Other information

Review other information context for Lenz Therapeutics, Inc..

Community

Review community context for Lenz Therapeutics, Inc..